

Randomized- blind crossover trial.  
Patients with active CD were given: azathioprine 3mg/kg/d for 4 months and placebo 4 months, sequence of therapy was randomized.

Primary endpoints: Improvement after 2 month therapy.

#### Results: N=26

- Of the 13 patients on AZA 2 developed allergic reaction to it and it was stopped. In placebo 2 stopped due to emergency urgent needed.
- Among AZA 6/11 vs 6/11 in placebo showed improvement with 9 and 8 patients respectively needing steroids within 4 months.

#### Conclusion:

This study does not provide evidence to support the effectiveness of azathioprine in the treatment of CD.

### Treatment Of Crohn's Disease With Azathioprine: A Controlled Evaluation

TABLE 3. Summary of objective and subjective parameters in patients receiving azathioprine (group A) or placebo (group B) during period 1

	Group A	Group B
Completed period 1 . . . . .	11/13 <sup>a, b</sup>	11/13 <sup>c</sup>
Subjective assessment		
Improvement . . . . .	6	6
No change . . . . .	5	5
Objective assessment		
Change in X-ray . . . . .	0/11	0/11
Change in absorption . . . . .	0/11	0/11
Change in weight <sup>d</sup>		
Gain . . . . .	3/11	3/11
Loss . . . . .	0/11	1/11
Change in joint symptoms		
Better . . . . .	2/4	1/3
No Change . . . . .	1/4	1/3
Worse . . . . .	1/4	1/3
Change in pain/diarrhea		
Improvement . . . . .	3/7	3/11
Cessation of rectal bleeding . . . . .	1/1	
Change in fistulae		
Healed . . . . .	1/5	1/5
Improved . . . . .	3/5	1/5
Unchanged . . . . .	1/5	3/5
Average prednisone dose		
Initial . . . . .	13.3 ± 3.5	19.8 ± 5.9
Final . . . . .	6.3 ± 1.6	7.8 ± 3.0

<sup>a</sup> Demoninator refers to total patient population at risk.

